FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression

Neuronetics, Inc., a privately-held medical device company and a leader in the field of neuromodulation, announced that the U.S. Food and Drug Administration (FDA) has cleared its NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy system for the treatment of depression. NeuroStar TMS Therapy(R) is specifically indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode. In clinical trials with NeuroStar TMS Therapy, these patients had been treated with a median of 4 medication treatment attempts, one of...

Want to see the full article?

• Purchase this article for only $3.00